

Cobenfy (xanomeline/trospium chloride)
Effective 04/01/2025

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
Exceptions	N/A		

Overview

Cobenfy (xanomeline/trospium) is a combination of a muscarinic agonist and muscarinic antagonist indicated for the treatment of schizophrenia in adults.

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted when all of the following criteria are met:

1. Member meets ONE of the following:
 - a. Member meets BOTH of the following:
 - i. Diagnosis of schizophrenia
 - ii. Trial and failure, contraindication, or intolerance to two of the following oral formulations: aripiprazole, asenapine, olanzapine, paliperidone, quetiapine IR/ER, risperidone, ziprasidone
 - b. Member has been started and stabilized on the requested medication (note: samples are not considered adequate justification for started and stabilized)

Continuation of Therapy

Requests for reauthorization will be approved when the following criteria are met:

1. Member has had a positive response to therapy

Limitations

1. Initial and reauthorization requests will be approved for 12 months
2. The following quantity limits apply:

Drug Name	Quantity Limit
Cobenfy	2 capsules per day

References

1. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). May 22, 2013. Accessed October 16, 2024. <https://psychiatryonline.org/doi/epub/10.1176/appi.books.9780890425596>.
2. Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. *N Engl J Med*. 2021;384:717-726. doi: 10.1056/NEJMoa2017015.
3. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. *Psychiatry (Edgmont)*. 2007;4(7):28-37.
4. Cobenfy (xanomeline/trospium chloride) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; September 2024.
5. Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia. *J Clin Psych*. 2022;1(InfoPack 1):SU21024IP1. doi: 10.4088/JCP.MS19053BR3C.
6. Institute for Clinical and Economic Review (ICER). KarXT for schizophrenia (final evidence report). March 11, 2024. Accessed October 3, 2024. https://icer.org/wp-content/uploads/2024/03/Schizophrenia_Final-Evidence-Report_For-Publication_03112024.pdf.
7. Jelastopulu E, Giourou E, Merikoulias G, et al. Correlation between the Personal and Social Performance Scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia. *BMC Psychiatry*. 2014;14:197. doi: 10.1186/1471-244X-14-197.
8. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. *Lancet*. 2024[a];403:10422:160-170. doi: 10.1016/S0140-6736(23)02190-6.
9. Kaul I, Sawchak S, Walling DP, et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. *JAMA Psychiatry*. 2024[b];81(8):749-756. doi: 10.1001/jamapsychiatry.2024.0785.
10. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, 3rd ed. American Psychiatric Association. 2021. Accessed October 15, 2024. <https://psychiatryonline.org/doi/epdf/10.1176/appi.books.9780890424841>.
11. Kidambi N, Elsayed OH, El-Mallakh. Xanomeline-trospium and muscarinic involvement in schizophrenia. *Neuropsychiatr Dis Treat*. 2023;19:1145-1151. doi: 10.2147/NDT.S406371.
12. Laucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: clinical implications. *Neuropsychopharmacology*. 2006;31(10):2318-25. doi: 10.1038/sj.npp.1301147.
13. Le Moigne A, Csernansky J, Leadbetter RA, et al. PANSS individual item and Marder dimension analyses from a pivotal trial of RBP-7000 (monthly extended-release risperidone) in schizophrenia patients. *J Clin Psychiatry*. 2021;82(5):21m13906. doi: 10.4088/JCP.21m13906.
14. Orzelska-Gorka J, Mikulska J, Wisniewska A, Biala G. New atypical antipsychotics in the treatment of schizophrenia and depression. *Int J Mol Sci*. 2022;23(18):10624. doi: 10.3390/ijms231810624.
15. Peng A, Chai J, Wu H, et al. New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists. *Neuropsychiatr Dis Treat*. 2024;20:607-620. doi: 10.2147/NDT.S455279.
16. Rabinowitz J, Mehnert A, Eerdeken M. To what extent do the PANSS and CGI-S overlap? *J Clin Psychopharmacol*. 2006; 26(3):303-307. doi: 10.1097/01.jcp.0000218407.10362.6e.
17. Singh A. Xanomeline and trospium: a potential fixed drug combination (FDC) for schizophrenia – a brief review of current data. *Innov Clin Neurosci*. 2022;19(10-12):43-47.



18. The PANSS Institute. PANSS. 2024. Accessed October 3, 2024. <https://panss.org/about-scales.php>

Review History

01/08/2025 – Reviewed at January P&T. Effective 04/01/2025.

